Eli Lilly's $1.3B acquisition of Verve Therapeutics caused a sharp rally, but with shares above the buyout price, I recommend ...

Key Takeaways Eli Lilly will acquire Verve for roughly $1 billionVerve is developing a one-time gene-editing treatment for ...

Asian shares are mixed and oil prices have advanced after the escalation of conflict in the Middle East hit Wall Street.

Scholar Rock (NASDAQ:SRRK) announced Wednesday that its lead candidate, apitegromab, in combination with Eli Lilly’s ...

With backers such as Regeneron’s venture arm, Actio Biosciences is working on medicines that counter a wide range of ...

Global shares were mostly higher Wednesday and oil prices slipped as investors awaited a decision on interest rates by the ...